ExodusPoint Capital Management’s AbbVie ABBV Stock Holding History

ExodusPoint Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,700	Closed	-$835K	–	1395
2024 Q4	$835K	Buy	4,700 +1,800	+62%	+$331K	0.01%	1002
2024 Q3	$572K	Sell	2,900 -20,800	-88%	-$3.88M	﹤0.01%	1142
2024 Q2	$4.07M	Buy	23,700 +7,500	+46%	+$1.24M	0.03%	485
2024 Q1	$2.94M	Buy	+16,200	New	+$2.79M	0.02%	564
2021 Q1	–	Sell	-20,000	Closed	-$2.14M	–	2064
2020 Q4	$2.14M	Buy	+20,000	New	+$1.92M	0.02%	515

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ExodusPoint Capital Management's ABBV Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 51,628 shares — an estimated $10.8M sold.

ExodusPoint Capital Management first reported a position in ABBV in Q2 2019 and held it in 19 quarters. The position peaked at $43.5M in Q2 2023. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

ExodusPoint Capital Management reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 51,628 AbbVie shares in Q2 2025, an estimated $10.8M.
ExodusPoint Capital Management first reported a position in AbbVie in Q2 2019 and held it in 19 quarters.
ExodusPoint Capital Management's AbbVie position peaked at $43.5M in Q2 2023.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.